NIP
VERV

Nicholas Investment Partners’s Verve Therapeutics VERV Stock Holding History

Nicholas Investment Partners’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-271,589
Closed -$10M – 217
2021
Q4 		$10M Buy
271,589
+139,289
+105% +$5.85M 0.63% 57
2021
Q3 		$6.22M Buy
+132,300
New +$7.78M 0.45% 82

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Nicholas Investment Partners's VERV Position: Q1 2022 in Review

Nicholas Investment Partners sold out of Verve Therapeutics (VERV) in Q1 2022, closing a stake of 271,589 shares — an estimated $10M sold.

Nicholas Investment Partners first reported a position in VERV in Q3 2021 and held it in 2 quarters. The position peaked at $10M in Q4 2021. 92 funds tracked by Wall St. Rank hold VERV as of Q1 2022.

  • Nicholas Investment Partners reported no remaining Verve Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Nicholas Investment Partners sold 271,589 Verve Therapeutics shares in Q1 2022, an estimated $10M.
  • Nicholas Investment Partners first reported a position in Verve Therapeutics in Q3 2021 and held it in 2 quarters.
  • Nicholas Investment Partners's Verve Therapeutics position peaked at $10M in Q4 2021.
  • 92 funds tracked by Wall St. Rank held Verve Therapeutics as of Q1 2022.

Based on Nicholas Investment Partners's 13F filing for Q1 2022, filed 10 May 2022.